National Rollout of Indigenous Cervical Cancer Vaccine 'Cervavac'
India has launched a nationwide immunization drive with 'Cervavac', its first indigenous Quadrivalent Human Papillomavirus (qHPV) vaccine, developed by the Serum Institute of India (SII) and the Department of Biotechnology (DBT). The vaccine is being provided free of cost to girls aged 9 to 14 years through the Universal Immunization Programme (UIP) to combat cervical cancer. This initiative, commencing in **May 2026**, aims to achieve 90% vaccination coverage by **2028**, significantly reducing the burden of the second most common cancer among women in India.
2-Minute Summary (TL;DR)
- India launched 'Cervavac', its first indigenous Quadrivalent Human Papillomavirus (qHPV) vaccine, in a national rollout in **May 2026**.
- Developed by **Serum Institute of India (SII)** in collaboration with the **Department of Biotechnology (DBT)**.
- The vaccine targets **cervical cancer**, the second most common cancer among women in India, caused by **HPV**.
- It is provided **free of cost** to girls aged **9 to 14 years** through the **Universal Immunization Programme (UIP)**.
- The government aims to achieve **90% vaccination coverage** among eligible girls by **2028**.
- Cervavac is significantly more affordable than imported alternatives, making large-scale immunization feasible.
- This initiative aligns with India's 'Atmanirbhar Bharat' vision and **WHO's global strategy** for cervical cancer elimination.
- The **Drugs Controller General of India (DCGI)** approved Cervavac in **July 2022**.
Why In News
The Ministry of Health and Family Welfare recently commenced the national rollout of 'Cervavac', India's first indigenously developed Quadrivalent Human Papillomavirus (qHPV) vaccine. This marks a significant milestone in the country's public health strategy, aiming to combat cervical cancer through widespread immunization. The launch integrates the vaccine into the existing Universal Immunization Programme (UIP) for adolescent girls.
Syllabus Connection
This topic connects to the advancements in indigenous vaccine development, public health initiatives, and the government's role in disease prevention and control, particularly focusing on non-communicable diseases like cancer through immunization programs.
Prelims vs Mains — What to Focus On
| Aspect | Prelims | Mains |
|---|---|---|
| What is Cervavac? | India's first indigenous Quadrivalent Human Papillomavirus (qHPV) vaccine. | A crucial step towards self-reliance in vaccine production and public health. |
| Who developed it? | Serum Institute of India (SII) in collaboration with Department of Biotechnology (DBT). | Demonstrates successful public-private partnership in health research and development. |
| Target Group & Delivery | Girls aged 9-14 years, free of cost via Universal Immunization Programme (UIP). | Aims to reduce cervical cancer burden, ensuring equitable access to preventive healthcare. |
| Disease Prevented | Cervical cancer, caused by Human Papillomavirus (HPV). | Addresses the second most common cancer among women in India, improving women's health. |
| National Goal | Achieve 90% vaccination coverage by 2028. | Reflects India's commitment to WHO's global strategy for cervical cancer elimination. |
How This Topic is Tested in Competitive Exams
| Exam | Frequency | Approx. Marks | What Gets Asked |
|---|---|---|---|
| SSC (CGL / CHSL / MTS) | High | 4–8 | Basic science, space missions, ISRO launches, and defence technology are standard SSC GK topics. |
| UPSC / State PCS | Medium | 5–8 | UPSC tests Science & Technology through governance: space policy, biotech regulations, cyber security. |
| State PCS / PSC | Medium | 3–5 | Space missions, defence acquisitions, and health research appear regularly. |
| Banking (IBPS / SBI) | Low | 1–2 | Occasionally tested via banking technology, fintech, or climate-science crossovers. |
Key Facts to Remember: National Rollout of Indigenous Cervical Cancer Vaccine 'Cervavac'
- India launched 'Cervavac', its first indigenous Quadrivalent Human Papillomavirus (qHPV) vaccine, in a national rollout in **May 2026**.
- Developed by **Serum Institute of India (SII)** in collaboration with the **Department of Biotechnology (DBT)**.
- The vaccine targets **cervical cancer**, the second most common cancer among women in India, caused by **HPV**.
- It is provided **free of cost** to girls aged **9 to 14 years** through the **Universal Immunization Programme (UIP)**.
- The government aims to achieve **90% vaccination coverage** among eligible girls by **2028**.
- Cervavac is significantly more affordable than imported alternatives, making large-scale immunization feasible.
- This initiative aligns with India's 'Atmanirbhar Bharat' vision and **WHO's global strategy** for cervical cancer elimination.
- The **Drugs Controller General of India (DCGI)** approved Cervavac in **July 2022**.
Practice Questions
Q1. Which of the following organizations, in collaboration with the Department of Biotechnology (DBT), developed 'Cervavac'?
- Bharat Biotech
- Serum Institute of India (SII)
- Dr. Reddy's Laboratories
- Zydus Cadila
Explanation: 'Cervavac', India's first indigenous qHPV vaccine, was developed by the **Serum Institute of India (SII)** in partnership with the **Department of Biotechnology (DBT)**. This collaboration highlights a successful public-private model for vaccine innovation in India.
Q2. Cervavac is primarily designed to prevent which type of cancer?
- Breast cancer
- Oral cancer
- Cervical cancer
- Lung cancer
Explanation: Cervavac is a Quadrivalent Human Papillomavirus (qHPV) vaccine specifically developed to prevent **cervical cancer**. Cervical cancer is predominantly caused by persistent infection with certain high-risk types of the Human Papillomavirus (HPV).
Q3. Under which government program is 'Cervavac' being rolled out nationally for free vaccination?
- National Health Mission (NHM)
- Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY)
- Universal Immunization Programme (UIP)
- Janani Shishu Suraksha Karyakram (JSSK)
Explanation: The national rollout of 'Cervavac' is being implemented through the **Universal Immunization Programme (UIP)**. This integration ensures that the vaccine reaches the target population of adolescent girls across the country free of cost, leveraging existing health infrastructure.
Q4. What is the primary target age group for free 'Cervavac' vaccination in India?
- Girls aged 0-5 years
- Girls aged 6-8 years
- Girls aged 9-14 years
- Women aged 15-25 years
Explanation: The 'Cervavac' vaccine is being provided free of cost to **girls aged 9 to 14 years** through the Universal Immunization Programme. This age group is targeted because vaccination before exposure to HPV offers the most effective protection against future infection and cervical cancer.
Q5. What is the government's ambitious target for 'Cervavac' vaccination coverage by the year 2028?
- 50%
- 70%
- 90%
- 100%
Explanation: The Government of India has set an ambitious goal to achieve **90% vaccination coverage** among eligible girls by the year **2028**. This high coverage rate is crucial for significantly reducing the incidence of cervical cancer and achieving public health impact.
How to Prepare Science & Technology for Government Exams — National Rollout of Indigenous Cervical Cancer Va…
For Railway exams, make flashcards for every major ISRO launch — name, payload, purpose, date. These repeat frequently.
For SSC, focus on defence acquisitions and their strategic significance rather than technical specs.
For UPSC, connect every scientific development to policy — climate targets, digital India, health policy.
Related Current Affairs
Test Your Knowledge on Today's Current Affairs
10 questions · 10 minutes · Based on today's GK updates. See how prepared you really are.
Start Daily Quiz